Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00811564 · ClinicalTrials.gov registry record · Phase 4
An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 148
- Enrollment target
NCT00811564 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 148 participants.
The verdict
NCT00811564, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 148 participants
- Enrollment target
Study Summary
A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects
Interventions
- DRUG fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
- DRUG latanoprost 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00811564
The ClinicalTrials.gov registry entry for NCT00811564 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution is the first listed.
NCT00811564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00811564 about?
NCT00811564 is a clinical study titled "An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects". A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects
What is the current status of trial NCT00811564?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 148 participants. The study started on 2008-12. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00811564?
The interventions under investigation include: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (DRUG), latanoprost 0.005% (DRUG).
Who is sponsoring clinical trial NCT00811564?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.